Gruppo Oncologico Del Nord-ovest

This study tests whether adding an immunotherapy drug (atezolizumab) to standard chemotherapy and targeted therapy can help people with a specific type of advanced colorectal cancer live longer without their disease getting worse. About 238 adults whose cancer has spread and cann…

This study tests whether giving a short course of targeted drugs before surgery can shrink tumors in people with colorectal cancer that can be removed. Participants must have a specific genetic change in their tumor and will receive a drug matched to that change for a few weeks b…

This study is for people with advanced head and neck cancer who are starting a standard immunotherapy drug called pembrolizumab. Researchers want to see if adding a special supplement (postbiotic) can reduce the immune-related side effects of the drug. About 45 participants will …

This study is testing a combination of three drugs (trastuzumab-deruxtecan, capecitabine, and bevacizumab) as a first treatment for people with a specific type of advanced colorectal cancer that has spread (HER-2 positive). The goal is to see how well this drug combo shrinks tumo…